The Effect Of Obesity On The Efficacy Of Fulvestrant In Breast Cancer Patients

Objective:To study the effect of obesity on the clinical efficacy of fulvestrant for hormone receptor-positive postmenopausal breast cancer.Methods:A retrospective analysis of the clinical case data and follow-up information of 127 breast cancer patients who regularly received fulvestrant 500 mg at the Cancer Hospital of Xinjiang Medical University from July 2016 to January 2020,and divided them into overweight and obese groups based on BMI(BMI≥24.0kg/m2)recombined with normal body(18.5<BMI<24.0 kg/m2).The main observation index is Progress Free Survival(PFS),and the secondary observation index is safety.Kaplan-Meier and Cox proportional hazard regression models were used for univariate and multivariate survival analysis,P<0.05 think the difference is statistically significant.Results:A total of 127 breast cancer patients who met the inclusion criteria were included.The BMI distribution is as follows:59 patients(46.6%)were classified as normal body weight,and 68 patients(53.4%)were overweight and obese.Kaplan-Meier analysis showed that after fulvestrant treatment,PFS was significantly correlated with BMI(P=0.048),bone metastasis(P=0.004)and visceral metastasis(P=0.035).The median PFS of the normal body was 12 months,and the overweight and obese group was PFS for 10 months,the difference was statistically significant(χ2=3.913,P=0.048)).The PFS of the normal weight group was longer than that of the overweight and obese group,and the difference was statistically significant(P<0.05).The BMI value(P=0.039)and the presence or absence of bone metastasis(P=0.012)significantly affected the patient’s PFS.After all patients were treated with fulvestrant,there were no serious adverse reactions and deaths related to fulvestrant treatment.Conclusion:Elevated BMI has a negative impact on treatment results.Patients of normal weight are more likely to benefit from Fulvestrant.